All In MedTech

Device Trial Radar · NCT07552597

Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma: MagMen-II

Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 254 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

254

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Dec 31, 2030

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Vastra Gotaland RegionGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Apr 27, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, international, phase III, multi-center, non- inferiority trial assessing the safety and efficacy of Magtrace® (superparamagnetic iron oxide, SPIO) in identification of lymph nodes in patients with cutaneous melanoma undergoing a sentinel lymph node biopsy (SLNB). Participants will be injected with both tracer methods Technetium (Tc99) plus Blue Dye (BD) and Magtrace®). They will undergo both a lymphoscintigraphy and a Magnetic Resonance Imaging (MRI) of the SLN basins. Before surgery, the participants will be randomly assigned on a 1:1 basis to either start the SLNB procedure using Tc99/BD and gamma-probe followed by Magtrace® and magnetic probe, or SLNB using Magtrace® followed by Tc99/BD. Randomization will be stratified by study site using permuted variable block sizes.

Conditions

  • Melanoma (Skin Cancer)

Interventions

  • Superparamagnetic Iron OxideDevice

    magnetic tracer for melanoma

  • Technetium (99mTc)Drug

    Radioactive tracer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SLN detectionTime frame: Within 6 weeks from surgery (10 weeks from enrollment)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.